Experimental Dual-Target CAR-T therapy takes aim at Hard-to-Treat plasma cell cancers
NCT ID NCT07519187
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new type of gene therapy called CAR 70-BCMA dual-target CAR-T for people with relapsed or refractory plasma cell neoplasms, including multiple myeloma. The therapy involves taking a patient's own immune cells, re-engineering them to recognize and attack cancer cells that carry two specific markers (CD70 and BCMA), and infusing them back. The study will enroll 20 participants to primarily evaluate safety and find the right dose, while also looking at how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR 70-BCMA dual-target CAR-T cells (a type of gene therapy that re-engineers a patient's own immune cells to attack cancer)
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat plasma cell cancers like multiple myeloma.
- What could go wrong
- This is a very early, small trial (20 people) focused mainly on safety. The therapy may not work or could cause serious side effects, and it is not yet known if it will lead to long-term disease control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Western Theater Command of PLA
RECRUITINGChengdu, Chengdu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact